Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

MNTA likely to partner on M254 as the potential is so big.

CW called it the sleeper program that is not going to take long to prove in phase trial starting 2nd half. All it has to do is show it is 10 times more powerful and few if any side affects.

Un met need on reduction of time to administer in a 4 Billion Dollar Market. Might show that they can even be able to do it subcutaneous. That would be big.

M281 they are also talking to the FDA to get in agreement on another rare disease with un met needs when we do the M281 trial. That second disease might get us a fast track designation.

Best take on what I heard on Merrill Lynch cc.

Breakout trade
WATCH for possible breakout above 23.04
Target: 24.54

Boing X 2